Steven Stein
Vermögen: 7 Mio $ am 31.05.2026
Vermögen: 7 Mio $ am 31.05.2026
Steven H. Stein hat die Position des Chief Medical Officer & Executive Vice President bei Incyte Corp. inne. Dr. Stein ist außerdem Mitglied des Vorstands von Kura Oncology, Inc. In seiner früheren Karriere war Dr. Stein Vice President-Global Oncology bei GlaxoSmithKline (New Jersey), SVP-US Clinical Development & Medical Affairs bei Novartis Oncology, Inc. und Senior VP-US Clinical Development & Medical Affair bei Novartis Pharmaceuticals Corp. Dr. Stein erhielt einen Doktortitel von der University of the Witwatersrand.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INCYTE CORPORATION 0.04% | 02.07.2026 | 76’150 ( 0.04% ) | 7 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| INCYTE CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 02.03.2015 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech invests in companies located in Israel. The firm targets companies operating in the fields of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirements. | Berater | - |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Unternehmen | Position | Ende |
|---|---|---|
| REPARE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 28.01.2026 |
| THESEUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 14.02.2024 |
| KURA ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 01.05.2023 |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | 01.02.2015 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01.02.2015 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Kura Oncology, Inc.
Kura Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
University of the Witwatersrand
University of the Witwatersrand Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline (New Jersey) | |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech invests in companies located in Israel. The firm targets companies operating in the fields of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirements. | Finance |
Repare Therapeutics, Inc.
Repare Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of novel cancer therapies | Health Technology |
Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and supplies drugs for cancer patients | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen